The anti-CXCL2 antibody significantly abrogated the tumor suppression effects of HVJ-E+poly I:C, whereas the anti-CXCL1 antibody had no effect on the combination treatment (Figures 3B and 3C). Here, CXCL2 is linked to neoplasm.